Osteocalcin and measures of adiposity: a systematic review and meta-analysis of observational studies

Li, Xiaoying; Liu, Yihui; Mathers, Julia; Cameron, Melissa; Levinger, Itamar; Yeap, Bu B.; Lewis, Joshua R.; Brock, Kaye E.; Brennan‐Speranza, Tara C.

doi:10.1007/s11657-020-00812-6

Cited by 13 publications

(11 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, recent studies have demonstrated that daily cheese intake, without concern to K2 and osteocalcin seems to reduce cardiac disease. 25 Positive effects of daily Jarlsberg® cheese intake were detected on the lipid pattern and the blood pressure in the previous doseresponse study. 12 Similar findings were not verified in the present studies.…”

Section: Discussionmentioning

confidence: 77%

See 1 more Smart Citation

Determination of maintenance Jarlsberg® cheese dose to keep the obtained serum osteocalcin level; a response surface pathway designed de-escalation dose study with individual starting values

Lundberg¹,

Holo

Holand

et al. 2021

Int J Clin Trials

View full text Add to dashboard Cite

Background: Daily maximum effective dose (MED) of Jarlsberg® increased the serum osteocalcin (tOC) level, vitamin K2 and affected the lipid pattern positively. The aim of the study was to estimate and verify a daily maintenance dose.Methods: 12 healthy female volunteers (HV) were included in a de-escalation study after a six week run-in period on the daily MED of 57 g Jarlsberg® cheese. A 3-level within-patient response surface pathway (RSP) design with individual starting values was developed. Another 12 HVs were included in a new study with a six week run-in period on MED followed with six weeks on the estimated maintenance dose. All HVs were premenopausal female between 20 and 52 years of age. The main variable in the studies was the tOC level.Results: tOC, cOC and the vitamin K2 variants increases significantly (p<0.01) during the run-in period on daily MED of Jarlsberg® in both studies. The maintenance daily dose was estimated to 45 g (95% CI: 38-52 g/day) and used in the new study. The tOC level was reduced from 19.8 ng/ml (95% CI: 12.0-27.6) obtained in the run-in period to 18.5 ng/ml (95% CI: 11.7-25.3) during the maintenance part. This represents a reduction of 6.6%. The sum of vitamin K2 variants changed from 0.58 ng/ml on MED of Jarlsberg® to 0.59 ng/ml (95% CI: 0.37-0.82) during the maintenance period.Conclusions: Daily MED of Jarlsberg® cheese increases tOC, cOC and the vitamin K2 level. The maintenance Jarlsberg® dose was estimated to 45 g/day and verified as sufficient.

show abstract

Section: Discussionmentioning

confidence: 77%

“…Low tOC levels are also associated with several diseases such as risk of metabolic syndrome, type 2 diabetes and obesity. 25 The daily MED of Jarlsberg® cheese was found to be 57g. 12 This is possibly unacceptably high in the long run for some people.…”

Section: Discussionmentioning

confidence: 98%

Determination of maintenance Jarlsberg® cheese dose to keep the obtained serum osteocalcin level; a response surface pathway designed de-escalation dose study with individual starting values

Lundberg¹,

Holo

Holand

et al. 2021

Int J Clin Trials

View full text Add to dashboard Cite

show abstract

“…Likewise, a negative correlation has been found between the ucOC/OCN ratio and BMI, which explains why overweight and obese patients have a lower ucOCN and ucOC/OCN ratio [15]. Some meta-analyses have observed that an increased total OCN and ucOCN are correlated with lower BMI and body fat percentage [16,17]. This association is specific to both ethnicity and the presence of obesity [16].…”

Section: Discussionmentioning

confidence: 99%

“…Some meta-analyses have observed that an increased total OCN and ucOCN are correlated with lower BMI and body fat percentage [16,17]. This association is specific to both ethnicity and the presence of obesity [16]. In healthy postmenopausal women, OCN has been considered as a marker of metabolic risk, which has a negative correlation with fasting plasma glucose, and lower concentrations of this osteokine being observed in obese women [18].…”

Section: Discussionmentioning

confidence: 99%

Pattern of Adiponectin, Osteocalcin, Irisin, FGF-21, and MCP-1 According to the Body Size Phenotype: Could They Be Markers of Metabolic Health in Mexican-Mestizo Middle-Aged Women?

et al. 2021

View full text Add to dashboard Cite

Variations in levels of some adipokines, myokines, osteokines, hepatokines and inflammatory cytokines contribute to abnormal glucose and lipid metabolism. The aim of this study was to determine the pattern of adiponectin, osteocalcin (OCN), irisin, FGF-21, and MCP-1 according to the body size phenotype of middle-aged women, and their associations with BMI, visceral adipose tissue (VAT), and HOMA-IR. A cross-sectional study in 265 women aged from 40 to 65 years was performed. The biochemical characteristics were evaluated in metabolically healthy normal weight, metabolically unhealthy normal weight, metabolically healthy obese, and metabolically unhealthy obese women. There was an association of OCN with BMI (r = −0.107; p = 0.047); adiponectin with BMI (r = −0.217; p = 0.001), insulin (r = −0.415; p = 0.0001), HOMA-IR (r = −0.429; p = 0.0001), and VAT (r = −0.134; p = 0.025); irisin with BMI (r = 0.604; p = 0.001), insulin (r = 0.446; p = 0.0001), HOMA-IR (r = 0.452; p = 0.0001), and VAT (r = 0.645; p = 0.0001); FGF−21 with insulin (r = −0.337; p= 0.030) and HOMA-IR (r = −0.341; p = 0.03); and MCP-1 with BMI (r = 0.481; p = 0.0001), VAT (r = 0.497; p = 0.001), insulin (r = 0.298; p= 0.001), and HOMA-IR (r = 0.255; p = 0.004). A multivariate analysis showed that an elevation of OCN (OR 1.4 (95%CI 1.06–1.81)) and a reduction of adiponectin (OR 0.9 (0.84–0.96)) were associated factors for a metabolic unhealthy phenotype in normal weight participants. Likewise, higher irisin (OR 1.007 (1.003–1.011)) and MCP-1 (1.044 (1.008–1.083)) were risk factors for a metabolic unhealthy phenotype in woman with obesity. OCN, adiponectin, irisin, FGF-21, and MCP-1 are associated with some metabolic parameters such as BMI, HOMA-IR, and VAT, and could be possible biomarkers of an unhealthy metabolic phenotype in middle-aged women.

show abstract

“…Both crosssectional and cohort studies support inverse associations of serum total osteocalcin with the risk of adverse metabolic outcomes [67]. A recent meta-analysis suggest that low concentration of osteocalcin is associated with low BMI and fat mass [76].…”

Section: Indicators Related To Blood Biomarkersmentioning

confidence: 91%

Early identification of metabolic syndrome risk: A review of reviews and proposal for defining pre-metabolic syndrome status

Gesteiro

Megía

Guadalupe‐Grau

et al. 2021

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

Aims: a) To analyze the relationship of known and emerging biomarkers/indicators for early risk identification of cardiometabolic health risk; b) to identify early risk markers to be used in both clinical and nonclinical settings; and c) to propose a definition of early risk identification in terms of pre-metabolic syndrome (PreMetSyn). Data synthesis: Pubmed/Medline, Web of Science, Embase, and Cochrane were searched for Systematic Reviews and Meta-analysis. Selected studies were evaluated, and relevant data were extracted and synthesized. Conclusions: Serum uric acid is a good predictive biomarker of metabolic syndrome (MetSyn) and has been associated with non-alcoholic liver fat disease (NAFLD) and type 2 diabetes. NAFLD emerges as an early risk indicator of PreMetSyn by itself. Muscle strength should also be included as an early risk marker of cardiometabolic health. High serum triglycerides and waist circumference confirm their predictive value regarding MetSyn. Indicators related to an inflammatory/proinflammatory status usually linked to MetSyn showed limited evidence as robust biomarkers for PreMetSyn. Authors suggest defining PreMetSyn related to cardiometabolic risk. It is also necessary to determine how close people are to the cut-off point of MetSyn components, including emerging indicators proposed by our review. Some biomarkers could be used as indicators of PreMetSyn, before any of the MetSyn components appear, allowing early health interventions to prevent its development. Defining a PreMetSyn status might consider both emerging indicators and those variables already included in the definition of MetSyn. New indicators should be considered to create a new risk score specifically meant for PreMetSyn.

show abstract

Osteocalcin and measures of adiposity: a systematic review and meta-analysis of observational studies

Cited by 13 publications

References 65 publications

Determination of maintenance Jarlsberg® cheese dose to keep the obtained serum osteocalcin level; a response surface pathway designed de-escalation dose study with individual starting values

Determination of maintenance Jarlsberg® cheese dose to keep the obtained serum osteocalcin level; a response surface pathway designed de-escalation dose study with individual starting values

Pattern of Adiponectin, Osteocalcin, Irisin, FGF-21, and MCP-1 According to the Body Size Phenotype: Could They Be Markers of Metabolic Health in Mexican-Mestizo Middle-Aged Women?

Early identification of metabolic syndrome risk: A review of reviews and proposal for defining pre-metabolic syndrome status

Contact Info

Product

Resources

About